We are pleased to welcome Robert (Bob) Palmisano as our newest member of the Saluda Medical Board of Directors. Mr. Palmisano currently serves as CEO and Chairman of medical technology SPAC Priveterra Acquisition. Read the full press release here: bit.ly/3uYMum0

Be sure to catch Nagy Mekhail’s, MD, PhD talk at ASIPP on the EVOKE Study 24m outcomes! For risks & important safety information, visit saludamedical.com/safety

Happy #NationalNursesDay! Thank you to all the amazing, caring, and devoted nurses who work tirelessly to keep us as healthy as possible. You inspire us.

It was a record-breaking week for Saluda at the 2022 International Neuromodulation Society Congress held in Barcelona! From our most robust scientific presence to-date to the numerous key engagements held with the global clinical community we continue to revolutionize the field of #neuromodulation #SCS

Congratulations to Jonathan Hagedorn, MD and the team at @iSpine Clinics on their first #ECAPStudy implant. Pictured here is Dr. Hagedorn with Saluda's VP of Therapy Development, Dean Karantonis. To learn more, visit ECAPStudy.com

Join us at the ASPN annual meeting where we’ll host a panel discussion on harnessing the power of Evoked Compound Action Potentials (#ECAPs) to treat pain. Click to register your interest: bit.ly/3nhmgGS For risks and important safety information: bit.ly/3HRktS9

Congratulations to David Rosenfeld, MD and the team at Alliance Spine and Pain Centers on their first #ECAPStudy implant. Pictured here is Dr. Rosenfeld with Saluda Medical’s Michael Dolan. To learn more, visit ECAPStudy.com

Don’t miss Dr. Steven Falowski’s presentation at the 4th annual ASPN meeting this Friday featuring late-breaking 24-month data from the Landmark EVOKE RCT. #SCS #ChronicPain #Neuromodulation #SmartSCS

We are pleased to welcome Sean Talarico to #TeamSaluda. Sean joins Saluda as Area Vice President of Sales, East, with more than 15 years of experience across a number of senior executive roles, including sales, commercial excellence, operations, and sales training. Welcome, Sean!

At the fourth annual ASPN meeting, Dr. Steven Falowski presented late-breaking 24-month data from the Landmark EVOKE RCT which demonstrated a new standard for holistic patient outcomes beyond pain relief. Read the full press release here: bit.ly/3zb3Ywz

Congratulations to Dr. Ron Boeding, MD, and the team at iSpine Clinics on another ECAP Study trial. To learn more about the ECAP Study, visit ECAPStudy.com.

Another momentous week at Saluda with yet another stellar class completing training. This group brings a wealth of experience, knowledge, and, most importantly, the desire and compassion for patient-centric care. #TeamSaluda

We are pleased to welcome Steven McQuillan, who joins us in the role of Chief Clinical Officer. Steve is an accomplished executive leader & has held a number of leadership roles across clinical science, regulatory and medical affairs. Welcome to #TeamSaluda!

ASPN 25! Risks and Important Safety Info lnkd.in/d2XZ_Asn ​​ ​ Rx Only ​​ ​ The Saluda Medical Evoke® SCS System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs.​ Evoke® System with EVA™ is available in select geographies.

We’re excited to be at International Neuromodulation Society's NSANZ Conference this week!​ ​ Let’s talk data-driven neuromodulation and the future of chronic pain management.​ See us at booth #12-13! #NSANZ2025 #Neuromodulation ​ ​ Risks and Important Safety Info: saludamedical.com/safety

The #EVOKE Study is the first double-blinded, pivotal randomized clinical trial to show the longest-lasting patient outcomes ever reported in spinal cord stimulation.​ It's the most rigorous study in #SCS history! ​ Risks and Important Safety Info: saludamedical.com/safety